Accessibility Menu
 
Relmada Therapeutics logo

Relmada Therapeutics

(NASDAQ) RLMD

Current Price$6.99
Market Cap$733.18M
Since IPO (2014)-88%
5 Year-81%
1 Year+2,206%
1 Month+50%

Relmada Therapeutics Financials at a Glance

Market Cap

$733.18M

Revenue (TTM)

$0.00

Net Income (TTM)

$57.39M

EPS (TTM)

$-1.47

P/E Ratio

-4.76

Dividend

$0.00

Beta (Volatility)

-0.01 (Low)

Price

$6.99

Volume

6.13

Open

$6.86

Previous Close

$6.99

Daily Range

$6.60 - $7.05

52-Week Range

$0.24 - $7.51

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Relmada Therapeutics

Industry

Pharmaceuticals

Employees

17

CEO

Sergio Traversa, PhD, MBA

Headquarters

Coral Gables, FL 33134, US

RLMD Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-94%

Return on Capital

-67%

Return on Assets

-61%

Earnings Yield

-21.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$733.18M

Shares Outstanding

104.89M

Volume

6.13

Short Interest

0.00%

Avg. Volume

1.55M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$59.10M

EBITDA

$59.10M

Operating Cash Flow

$45.79M

Capital Expenditure

$0.00

Free Cash Flow

$45.79M

Cash & ST Invst.

$93.01M

Total Debt

$0.00

Relmada Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$733.18M

N/A

Market Cap/Employee

$43.13M

N/A

Employees

17

N/A

Net Income

$19.87M

-6.5%

EBITDA

$20.57M

N/A

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$93.01M

+107.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-61.05%

N/A

Return on Invested Capital

-67.49%

N/A

Free Cash Flow

$31.19M

+454.5%

Operating Cash Flow

$31.19M

+454.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VXRTVaxart, Inc.
$0.61+0.00%
IMUXImmunic, Inc.
$1.16+0.87%
RPTXRepare Therapeutics Inc.
$2.65+0.00%
CBUSCibus, Inc.
$1.98+2.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$177.28+0.01%
TSLATesla
$360.45-0.05%
MUMicron Technology
$366.03-0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%

Questions About RLMD

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.